About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Dynavax Technologies image

Dynavax Technologies

Rank#4861
Market Cap1.82B
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Historyarrow

Dynavax Technologies Corporation was founded as an immunology-focused company in 1997 by Michael A. Ostrakhovsky, M.D., and Hasmukh P. Wani, Ph.D. The company went public in 2005 and is traded on the NASDAQ. Dynavax has licensed a number of technologies from the University of California and other academic and biopharmaceutical companies.

Missionarrow
Dynavax's mission is to discover, develop and commercialize innovative immunotherapies that will have a meaningful impact on patients’ lives.
Visionarrow
At Dynavax, we are dedicated to becoming the leader in immuno-oncology and other immune-mediated indications by helping to re-educate and modulate the immune system.
Referencesarrow

https://in.investing.com/equities/dynavax-tech

https://finance.yahoo.com/quote/DVAX/profile?p=DVAX

https://www.crunchbase.com/organization/dynavax-technologies

https://sec.report/CIK/0001029142

https://companiesmarketcap.com/

https://www.dynavax.com

Share

Leadership team
M
Mr. Ryan Spencer (CEO & Director)
M
Mr. David F. Novack (Pres & COO)
M
Ms. Kelly MacDonald (Sr. VP & CFO)
Products / Services
Biopharma, Biotechnology, Clinical Trials, Health Care, Medical Device
Number of Employees
100 - 500
Address
Berkeley, California, United States
Established
1996-01-01
Company Registration
SEC CIK number: 0001029142
Net Income
S_100M_500M
Revenue
500M - 1B
Traded as
DVAX
Website
https://www.dynavax.com
Social Media
linkedin
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo